<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 71-year-old Caucasian man diagnosed with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> developed interstitial and alveolar <z:mp ids='MP_0003045'>fibrosis</z:mp> after receiving a 7-day course of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The patient's pulmonary function began to deteriorate immediately after the administration of his chemotherapy regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Other potential causes of pulmonary toxicity were ruled out such as <z:mp ids='MP_0001799'>viral</z:mp>, fungal, and <z:mp ids='MP_0001794'>bacterial</z:mp> pathogens, as well as other concomitant drugs </plain></SENT>
<SENT sid="3" pm="."><plain>To our knowledge, this is the first case report documenting biopsy-proven interstitial and alveolar <z:mp ids='MP_0003045'>fibrosis</z:mp> associated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency of this adverse drug reaction is unknown but may become more evident with increasing exposure of the population to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
</text></document>